Genentech, a unit of Roche Holding AG (RHHBY), on Monday announced that its investigational therapy fenebrutinib met the primary endpoint in the Phase III FENhance 2 study in patients with relapsing multiple sclerosis (RMS).
FENhance 2 is one of two pivotal, similarly designed Phase III studies — FENhance 1 and FENhance 2 — evaluating fenebrutinib versus teriflunomide in adult patients with RMS. According to the company, fenebrutinib significantly reduced the annualized relapse rate (ARR) compared with the approved multiple sclerosis therapy teriflunomide over a treatment period of at least 96 weeks.
In addition, the Phase III FENtrepid study evaluating fenebrutinib versus Ocrevus in patients with primary progressive multiple sclerosis (PPMS) met its primary endpoint, demonstrating non-inferiority to ocrelizumab — currently the only approved therapy for PPMS.
"Fenebrutinib substantially reduced the number of relapses in RMS and slowed disability progression in PPMS. These unprecedented results suggest that fenebrutinib could potentially become a best-in-disease medicine as the first high-efficacy, oral treatment for people with RMS or PPMS," said Levi Garraway, Genentech's chief medical officer and head of Global Product Development.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.